Oragenics, Inc. Files 10K And Provides Company Update
Oragenics, Inc. Files 10K And Provides Company Update
Oragenics, Inc. (the "Company") (NYSE:OGEN), a company focused on developing unique, intranasal pharmaceuticals for the treatment of neurological disorders, today announced that it has filed its annual report on March 29, 2024. The Company is pleased to report it has executed on its strategy to diversify its product development portfolio and makes progress in transforming the Company to create long term value. Some key items that have helped to improve the Company moving forward are:
- The Company acquired a platform technology intended to treat multiple neurological disorders. The first target indication is for concussion and the technology has successfully completed a Phase I trial.
- Raised approximately $ 2.1 million in a public offering and $890,000 in a private transaction.
- Hired a Chief Medical Officer: Dr James Kelly MD, is a thought leader in brain injury including concussion.
- Added two new Board members: John Gandolfo and Bruce Cassidy.
- Created a subsidiary in Australia to take advantage of R&D rebates offered by the Australian government.
- Contracted with a leading Contract Research Organization to oversee our Phase II clinical trial.
- Manufacturing drug in preparation for our Phase II trial.
We are excited about the progress the Company has made in the past several months. We are creating a team with the experience and drive to further our neurological drug candidates through clinical trials during 2024," commented Michael Redmond, President of Oragenics.
As previously disclosed in its Annual Report on Form 10-K for the year ended December 31, 2023, which was filed on March 29, 2024 with the Securities and Exchange Commission, the audited consolidated financial statements contained an unqualified audit opinion from its independent registered public accounting firm that included an explanatory paragraph related to the Company's ability to continue as a going concern. See further discussion in footnote 1 of the Company's consolidated financial statements included in the Company's Annual Report on Form 10-K.
Oragenics, Inc. (the "Company") (NYSE:OGEN), a company focused on developing unique, intranasal pharmaceuticals for the treatment of neurological disorders, today announced that it has filed its annual report on March 29, 2024. The Company is pleased to report it has executed on its strategy to diversify its product development portfolio and makes progress in transforming the Company to create long term value. Some key items that have helped to improve the Company moving forward are:
Oragenics, Inc.（“公司”）（紐約證券交易所代碼：OGEN）是一家專注於開發用於治療神經系統疾病的獨特鼻內藥物的公司，今天宣佈已於2024年3月29日提交了年度報告。該公司高興地報告，它已經執行了多元化產品開發組合的戰略，並在公司轉型以創造長期價值方面取得了進展。一些有助於改善公司前進的關鍵項目是：
- The Company acquired a platform technology intended to treat multiple neurological disorders. The first target indication is for concussion and the technology has successfully completed a Phase I trial.
- Raised approximately $ 2.1 million in a public offering and $890,000 in a private transaction.
- Hired a Chief Medical Officer: Dr James Kelly MD, is a thought leader in brain injury including concussion.
- Added two new Board members: John Gandolfo and Bruce Cassidy.
- Created a subsidiary in Australia to take advantage of R&D rebates offered by the Australian government.
- Contracted with a leading Contract Research Organization to oversee our Phase II clinical trial.
- Manufacturing drug in preparation for our Phase II trial.
- 該公司收購了一項旨在治療多種神經系統疾病的平台技術。第一個目標適應症是腦震盪，該技術已成功完成I期試驗。
- 通過公開募股籌集了約210萬美元，通過私人交易籌集了890,000美元。
- 聘請首席醫療官：醫學博士詹姆斯·凱利博士是包括腦震盪在內的腦損傷領域的思想領袖。
- 增加了兩名新的董事會成員：約翰·甘道夫和布魯斯·卡西迪。
- 在澳大利亞成立了一家子公司，以利用澳大利亞政府提供的研發折扣。
- 與一家領先的合同研究組織簽約，監督我們的二期臨床試驗。
- 製造藥物，爲我們的二期試驗做準備。
We are excited about the progress the Company has made in the past several months. We are creating a team with the experience and drive to further our neurological drug candidates through clinical trials during 2024," commented Michael Redmond, President of Oragenics.
我們對公司在過去幾個月中取得的進展感到興奮。Oragenics總裁邁克爾·雷德蒙德評論說，我們正在組建一支具有豐富經驗和動力的團隊，通過臨床試驗進一步發展我們的神經系統候選藥物。
As previously disclosed in its Annual Report on Form 10-K for the year ended December 31, 2023, which was filed on March 29, 2024 with the Securities and Exchange Commission, the audited consolidated financial statements contained an unqualified audit opinion from its independent registered public accounting firm that included an explanatory paragraph related to the Company's ability to continue as a going concern. See further discussion in footnote 1 of the Company's consolidated financial statements included in the Company's Annual Report on Form 10-K.
正如先前在2024年3月29日向美國證券交易委員會提交的截至2023年12月31日的10-K表年度報告中披露的那樣，經審計的合併財務報表包含其獨立註冊會計師事務所的無保留審計意見，其中包括與公司繼續經營能力有關的解釋性段落。請參閱公司10-K表年度報告中公司合併財務報表腳註1中的進一步討論。
譯文內容由第三人軟體翻譯。
風險及免責聲明
- 分享到weixin
- 分享到qq
- 分享到facebook
- 分享到twitter
- 分享到微博
- 粘贴板
使用瀏覽器的分享功能，分享給你的好友吧